Ultrasound Molecular Imaging with Targeted Microbubbles for Cancer Diagnostics: From Bench to Bedside - 28/01/19
pages | 7 |
Iconographies | 5 |
Vidéos | 0 |
Autres | 0 |
Abstract |
Background |
Ultrasound plays an important role in cancer diagnosis. B-mode imaging and contrast-enhanced ultrasound are routinely used to detect cancerous lesions in breast and liver. The use of ultrasound contrast agents (UCAs) such as microbubbles (MBs), which can be functionalized with targeting ligands, has further enabled ultrasound molecular imaging (USMI) of specific molecular markers in pre-clinical and the first clinical studies. As targeted MBs have a diameter of 1–4 μm, they are limited to the blood vasculature upon intravenous injection, and can bind to markers of the vascular endothelium. USMI with targeted MBs was applied for imaging of markers of inflammation, angiogenesis, and the tumor endothelium.
Aim |
The present review provides an introduction to USMI and presents currently available UCAs, targeting strategies, pre-clinical targets, proposed applications, and the first clinical studies with USMI to guide novel users and assess the technique's potential for clinical use.
Le texte complet de cet article est disponible en PDF.Graphical abstract |
Highlights |
• | USMI provides information about markers that are useful for cancer diagnostics. |
• | UCAs are functionalized with targeting ligands for molecular imaging. |
• | Imaging strategies allow distinction between circulating and attached MBs. |
• | Targeted MBs are used for cancer angiogenesis imaging in pre-clinical studies. |
• | BR55 proved the feasibility of clinical cancer imaging by USMI. |
Plan
Vol 40 - N° 1
P. 3-9 - février 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?